文献速递MDS 与骨髓增殖性肿瘤

治疗相关性与原发骨髓增生异常综合征患者的临床结局及风险分层工具预后效用比较:MDS临床研究联盟报告

Comparison of clinical outcomes and prognostic utility of risk stratification tools in patients with therapy-related vs de novo myelodysplastic syndromes: a report on behalf of the MDS Clinical Research Consortium.
PubMed 文献 · Leukemia · 2017-01-23

在1950例MDS患者中识别出370例(19%)治疗相关性MDS(t-MDS),其中位生存期显著短于原发MDS(19个月 vs 46个月,P<0.005)。所有风险模型均能区分t-MDS的生存(各模型P<0.005),MPSS、TPSS和IPSS-R预测效能最佳。

要点

  • t-MDS占MDS的19%,中位生存19个月,显著短于原发MDS的46个月(P<0.005)。
  • IPSS、IPSS-R、MPSS、WPSS、TPSS均能区分t-MDS的生存(各模型P<0.005)。
  • AIC评分显示MPSS(2316)、TPSS(2343)和IPSS-R(2343)预测效能最佳。

核心结论

  • 常规风险分层模型可识别t-MDS中具有不同临床结局的亚组。
  • MPSS、TPSS和IPSS-R提供最佳的预测效能。

研究设计与样本

  • 在1950例MDS患者中识别出370例(19%)t-MDS患者。
  • 既往治疗包括单纯化疗(48%)、放化疗(31%)和单纯放疗(21%)。
  • 比较IPSS、IPSS-R、MPSS、WPSS和TPSS在t-MDS患者中的表现,采用Akaike信息准则(AIC)评估模型拟合优度。

主要发现

  • t-MDS患者中位生存期显著短于原发MDS(19个月 vs 46个月,P<0.005)。
  • 所有模型均能区分t-MDS的生存(各模型P<0.005)。
  • 在每个风险模型中,t-MDS患者死亡风险均显著高于原发MDS,且在所有风险组别中生存均劣于原发MDS。
  • AIC评分(越低越好)为:MPSS 2316、TPSS 2343、IPSS-R 2343、WPSS 2361、IPSS 2364。

关键数值与推荐

  • AIC评分(越低越好):MPSS 2316、TPSS 2343、IPSS-R 2343、WPSS 2361、IPSS 2364。
  • t-MDS中位生存19个月 vs 原发MDS 46个月(P<0.005)。
  • 各模型区分t-MDS生存的P值均<0.005。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

While therapy-related (t)-myelodysplastic syndromes (MDS) have worse outcomes than de novo MDS (d-MDS), some t-MDS patients have an indolent course. Most MDS prognostic models excluded t-MDS patients during development. The performances of the International Prognostic Scoring System (IPSS), revised IPSS (IPSS-R), MD Anderson Global Prognostic System (MPSS), WHO Prognostic Scoring System (WPSS) and t-MDS Prognostic System (TPSS) were compared among patients with t-MDS. Akaike information criteria (AIC) assessed the relative goodness of fit of the models. We identified 370 t-MDS patients (19%) among 1950 MDS patients. Prior therapy included chemotherapy alone (48%), chemoradiation (31%), and radiation alone in 21%. Median survival for t-MDS patients was significantly shorter than for d-MDS (19 vs 46 months, P<0.005). All models discriminated survival in t-MDS (P<0.005 for each model). Patients with t-MDS had a significantly higher hazard of death relative to d-MDS in every risk model, and had inferior survival compared to patients with d-MDS within all risk group categories. AIC Scores (lower is better) were 2316 (MPSS), 2343 (TPSS), 2343 (IPSS-R), 2361 (WPSS) and 2364 (IPSS). In conclusion, subsets of t-MDS patients with varying clinical outcomes can be identified using conventional risk stratification models. The MPSS, TPSS and IPSS-R provide the best predictive power.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Zeidan AM, Al Ali N, Barnard J, et al. Comparison of clinical outcomes and prognostic utility of risk stratification tools in patients with therapy-related vs de novo myelodysplastic syndromes: a report on behalf of the MDS Clinical Research Consortium. Leukemia. 2017. PMID: 28111463. doi:10.1038/leu.2017.33

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。